Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
100%
Blinatumomab
100%
Hematopoietic Cell Transplantation
50%
Graft-versus-host Disease (GvHD)
33%
Non-responders
33%
Mortality Rate
16%
Leukemia Patients
16%
No Significant Difference
16%
High Risk
16%
T Cells
16%
Neutropenia
16%
High-risk Acute Leukemia
16%
Adverse Events
16%
First Cycle
16%
Phase II Study
16%
Risk for Relapse
16%
4-cycle
16%
Median Time
16%
Non-relapse Mortality
16%
First Year
16%
Single Center
16%
Day Range
16%
Cumulative Incidence
16%
Between-group
16%
Memory CD8+ T Cells
16%
Specific T Cells
16%
Neurotoxicity
16%
Overall Survival Progression-free Survival
16%
Cytokine Release
16%
Time-to-treatment
16%
Treatment Cycle
16%
CD8 T Cell Subsets
16%
Match Analysis
16%
Effector Memory
16%
T Cell Immunoglobulin mucin-3
16%
T-cell Profile
16%
Immune Milieu
16%
Inhibitory Checkpoint Molecule
16%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
100%
Hematopoietic Cell
100%
Cell Transplantation
100%
Blinatumomab
100%
T Cell
50%
Mortality Rate
16%
Overall Survival
16%
Adverse Event
16%
Progression Free Survival
16%
Neutropenia
16%
Immunity
16%
Identified Patient
16%
Immunoglobulin
16%
Cumulative Incidence
16%
Acute Graft Versus Host Disease
16%
Chronic Graft Versus Host Disease
16%
Cytokine Release
16%
Cytotoxic T-Cell
16%
Neurotoxicity
16%
Mucin
16%
T Cell Subset
16%
Immunology and Microbiology
Hematopoietic Cell
100%
Lineage
100%
Cell Transplantation
100%
Blinatumomab
100%
T Cell
50%
Cytotoxic T-Cell
16%
Immunity
16%
Intravenous Immunoglobulin
16%
Overall Survival
16%
Acute Graft Versus Host Disease
16%
Chronic Graft Versus Host Disease
16%
T Cell Subset
16%
Cytokine Release
16%
Mortality Rate
16%
Progression Free Survival
16%
Mucin
16%